European journal of nuclear medicine and molecular imaging · 2024
Bacteria-targeted imaging using vancomycin-based positron emission tomography tracers can distinguish infection from sterile inflammation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spoelstra G B, Braams L M, IJpma F F A, van Oosten M, Feringa B L, Szymanski W, Elsinga P H, van Dijl Jan Maarten
Аннотация
INTRODUCTION: Bacterial infections pose major challenges in medicine. To guide effective infection treatment, faster and more accurate diagnostic modalities are needed. Bacteria-targeted molecular imaging can meet these needs. The present study was aimed at the in vivo evaluation of two 18F-vancomycin-based PET tracers, for detection of deep-seated Gram-positive bacterial infections. These tracers were bench-marked against the current standard of care, [18F]FDG.
METHODS: The potential of [18F]BODIPY-FL-vancomycin and [18F]PQ-VE1-vancomycin ([4+2]photocycloadduct of 9,10-phenanthrenequinone-vancomycin and [18F]fluorinated vinyl ether) to distinguish bacterial infections from sterile inflammation was evaluated in a murine myositis model. Tracer specificity was assessed by infecting mice either with the Gram-positive bacterium Staphylococcus aureus (n = 12) or the Gram-negative bacterium Escherichia coli (n = 12). The contralateral leg was injected with Cytodex beads to induce sterile inflammation, or with phosphate-buffered saline for control. In parallel, mice were imaged with [18F]FDG (n = 12). Dynamic positron emission tomography (PET) measurements, biodistribution analyses, and immunohistopathology were performed to determine tracer distribution and bacterial burden.
RESULTS: Both 18F-vancomycin-PET tracers accumulated at sites of infection, but not at sites of sterile inflammation, in contrast to [18F]FDG. The tracers exhibited distinct biodistribution profiles, with [18F]BODIPY-FL-vancomycin being cleared more rapidly. Both 18F-vancomycin-PET tracers displayed significant target to non-target ratios of 2.95 for [18F]BODIPY-FL-vancomycin and 1.48 for [18F]PQ-VE1-vancomycin.
CONCLUSION: Vancomycin-based PET is a potentially attractive approach to distinguish Gram-positive bacterial infections from sterile inflammation.
METHODS: The potential of [18F]BODIPY-FL-vancomycin and [18F]PQ-VE1-vancomycin ([4+2]photocycloadduct of 9,10-phenanthrenequinone-vancomycin and [18F]fluorinated vinyl ether) to distinguish bacterial infections from sterile inflammation was evaluated in a murine myositis model. Tracer specificity was assessed by infecting mice either with the Gram-positive bacterium Staphylococcus aureus (n = 12) or the Gram-negative bacterium Escherichia coli (n = 12). The contralateral leg was injected with Cytodex beads to induce sterile inflammation, or with phosphate-buffered saline for control. In parallel, mice were imaged with [18F]FDG (n = 12). Dynamic positron emission tomography (PET) measurements, biodistribution analyses, and immunohistopathology were performed to determine tracer distribution and bacterial burden.
RESULTS: Both 18F-vancomycin-PET tracers accumulated at sites of infection, but not at sites of sterile inflammation, in contrast to [18F]FDG. The tracers exhibited distinct biodistribution profiles, with [18F]BODIPY-FL-vancomycin being cleared more rapidly. Both 18F-vancomycin-PET tracers displayed significant target to non-target ratios of 2.95 for [18F]BODIPY-FL-vancomycin and 1.48 for [18F]PQ-VE1-vancomycin.
CONCLUSION: Vancomycin-based PET is a potentially attractive approach to distinguish Gram-positive bacterial infections from sterile inflammation.